A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms BIRCH
- Sponsors Genentech; Roche
- 18 Oct 2017 Updated efficacy results presented at the 18th World Conference on Lung Cancer.
- 02 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2018.
- 13 Jun 2017 Results published in the Journal of Clinical Oncology